Research and Development
Since the establishment of SUCB, the company has always focused on R&D as constantly being innovative and improving sources. The company has adhered to the principle of innovation to the development of high-quality biopharmaceutical and vaccine products for the benefit of the community.
Each year the company invests more than 10% in sales and marketing making the company as a leader in the industry. Over the past years of development, SUCB possesses the drug development platform based on prokaryotic and eukaryotic expression systems. Marketed products include endocrine, orthopedics, ophthalmology, anti-infection and other treatment areas. For conventional drug formulation, SUCB has successfully developed enteric coated capsules, as well as cartridge preparations. SUCB received a patent protection for the product being developed and be a part of PCT national phase. R&D Center is currently developing a few innovative product now in clinical stage that would contribute to SUCB’s future and the health of the community.
In product development, SUCB has acknowledged a lot of projects from the government and for the city. SUCB achieved the “ National Major New Drug Innovation”, “National Major New Drug Plan”, “National Torch Plan Industrialization Demonstration Project” and among others.
SUCB’s strong technological platform has established a close cooperation with well-known research institutes and biotech companies at home and abroad. SUCB has continuously created innovative products whether it is development of new drug formulation, the introduction and commercialization of new drug, or the improvement and optimization of production processes.
1． R16
R16 plays an important role in the growth and development of the human body by providing multiple physiological functions such as promoting bone, internal organs and body growth, accelerating protein synthesis, accelerating fat and mineral metabolism, etc.
R16 has already been approved for the treatment of 10 diseases, such as Pediatric hormone deficiency, adult hormone deficiency, idiopathic short stature, intrauterine growth retardation, Turner syndrome and AIDS.
SUCB’s R16 product has been approved for production, the product has undergone process improvement, quality stability, performance advancement that will minimize cost of production.
2． R27
R27 promotes bone synthesis by binding to receptors on osteoblasts. R27 has been approved for poste menstrual women with osteoporosis, male hypogonodiac osteoporosis and glucocorticoid-induced osteoporosis treatment.
As an alternative with traditional drugs for the treatment of osteoporosis, R27 can have a better therapeutic effect to promote bone formation and prevent bone loss.
Our R27 product is liquid injection format , it will have better ease of administration and will improve patient compliance, and will also form a more comprehensive composite product line.
3.R30
R30 is a monoclonal antibody fragment against vascular endothelial growth factor (VEGF) that binds to VEGF and inhibits its induction of angiogenesis and vascular leakage. The product has been approved for treatment of related ophthalmic diseases such as wet age-related macular degeneration (AMD), diabetic maculopathy, retinal vascular occlusion, and choroidal neovascularization.
Our company's R30 product is developed according to the concept of biosimilar drug products and has now submitted a clinical application.
4． R24
Helicobacter pylori infection is associated with the onset of stomach disease. In 1994, the World Health Organization/International Agency for Research on Cancer designated Helicobacter pylori as a class I carcinogen. R24 is a Class 1 preventive biological product used to prevent Helicobacter pylori infection.
At present, our company's R24 product is in the preclinical research stage, its invention patent has been authorized (CN 101732705B), and PCT patents are in the actual examination stage in many countries.